Deepecho has entered a strategic partnership with Rosh Maternal & Fetal Medicine in New York, signaling a significant move in the use of artificial intelligence for pregnancy care. The collaboration connects Deepecho’s AI-driven ultrasound capabilities with one of the city’s most established clinics for high risk pregnancies. Together, the two organizations aim to make prenatal care safer, smarter, and more accessible for mothers and babies worldwide.
Rosh MFM’s Clinical Strength in High Risk Pregnancy Care
Rosh Maternal & Fetal Medicine has built a strong position in New York as a reference center in women’s health, particularly for complex and high risk pregnancies. The clinic provides advanced ultrasound and imaging, personalized prenatal care, and comprehensive genetic counseling for patients facing challenging clinical situations. This depth of experience creates a robust real world environment in which to test, refine, and scale AI solutions for maternal fetal medicine.
Leadership and Expertise Behind the Partnership
The clinic is led by Dr. Daniel Roshan, Founder, CEO, and Lead Physician at Rosh MFM, who completed his Maternal Fetal Medicine training at Johns Hopkins University and previously directed perinatology services at NYU Langone. With more than two decades of practice, he is recognized for his expertise in managing conditions such as gestational diabetes, preeclampsia, preterm labor, and genetic disorders during pregnancy. His leadership provides a strong clinical backbone for evaluating how AI tools can support better diagnostic decisions and patient outcomes.
Advancing AI Driven Fetal Medicine in Real Clinical Settings
Through this partnership, Deepecho and Rosh MFM plan to deploy and iteratively improve AI algorithms directly within day to day clinical workflows. The aim is to use real world ultrasound data and continuous feedback from clinicians to ensure that AI outputs are reliable, interpretable, and aligned with how maternal fetal specialists actually practice. By anchoring development in real clinical use, the partners intend to move beyond theoretical models and deliver tools that genuinely help sonographers and physicians during examinations.
Focus on New Imaging Biomarkers and Clinical Research
A key pillar of the collaboration is research into new imaging biomarkers for pregnancy related conditions such as preeclampsia, gestational diabetes, and preterm birth. Deepecho’s technology will be used to explore how AI can detect subtle patterns that may signal elevated risk earlier than conventional approaches. The partners also expect this research to support the publication of clinical findings and the creation of educational content that helps healthcare professionals integrate AI responsibly.
Voices from Deepecho and Rosh MFM
Deepecho’s Chief Medical Officer, Dr. Saad Slimani, highlighted the opportunity to merge the company’s technology with Rosh MFM’s clinical expertise to rethink what is possible in maternal fetal medicine. He emphasized that the goal is not to replace clinicians, but to extend their reach by enhancing the quality and consistency of ultrasound based assessments. Dr. Roshan echoed this view, noting that the combination of long standing clinical experience and advanced AI can raise diagnostic accuracy and improve outcomes for both mothers and babies.
For Deepecho, the partnership represents a concrete step in its mission to equip healthcare professionals with intelligent tools that support better diagnosis and smoother care pathways. By working with one of the most trusted and innovative maternal fetal medicine clinics in the United States, the company strengthens its ability to validate AI solutions in demanding real world conditions. If successful, the collaboration could help set new standards for how AI is used in prenatal care and contribute to a future in which every ultrasound becomes a more powerful source of insight and protection for mothers and their children.